Category: 871115-32-1

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent， Recommanded Product: 871115-32-1, Which mentioned a new discovery about 871115-32-1

The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more beta-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, Recommanded Product: 871115-32-1, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 871115-32-1

Reference：
Piperidine – Wikipedia,
Piperidine | C5H18606N – PubChem

Application of 871115-32-1, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.871115-32-1, Name is tert-Butyl 4-amino-4-(aminomethyl)piperidine-1-carboxylate, molecular formula is C11H23N3O2. In a Patent，once mentioned of 871115-32-1

The invention discloses a novel spiro compound and a synthesis method, and relates to a novel spiro compound and a synthesis method thereof. The synthesis method comprises the following steps: dissolving the compound III in an organic solvent, stirring uniformly, adding an organic solvent, cooling the compound IV, adding the acid-binding agent to the organic 0 C solvent, heating the compound IV and the acid-binding agent into the reaction liquid to react, and treating to obtain the novel spirocyclic compound after the reaction is finished, and the compound III, the acid-binding agent and the organic solvent are added dropwise to react; and the reaction liquid, the compound III and the acid-binding agent are added dropwise. The beneficial effects of the invention are that: To the novel spiro compound I, compound II and compound III are adopted as starting materials, and the novel spiro compound I is synthesized through two steps of simple reaction, so that the novel spiro compound I has important significance for finding new, better curative effect drug molecules and is easy to obtain, mild, simple and convenient in process, high in product yield, and suitable for large-scale production. (by machine translation)

The reactant in an enzyme-catalyzed reaction is called a substrate. Enzyme inhibitors cause a decrease in the reaction rate of an enzyme-catalyzed reaction.I hope my blog about 871115-32-1 is helpful to your research. Application of 871115-32-1

Reference：
Piperidine – Wikipedia,
Piperidine | C5H18609N – PubChem

Application of 871115-32-1, Catalysts are substances that increase the reaction rate of a chemical reaction without being consumed in the process. 871115-32-1, Name is tert-Butyl 4-amino-4-(aminomethyl)piperidine-1-carboxylate, molecular formula is C11H23N3O2. In a Patent£¬once mentioned of 871115-32-1

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Application of 871115-32-1, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 871115-32-1, in my other articles.

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H18604N – PubChem